LUGANO-OXFORD - ESMO, the leading European professional organisation for medical oncology announced today that Professor Fabrice André, MD, PhD, will be the new interim Editor-in-Chief of Annals of Oncology as of 14 September 2017.
Annals of Oncology is ESMO’s flagship scientific journal with an Impact Factor of 11.855, according to the latest Journal Citation Reports®* (1). Annals of Oncology now sits as 10th in the field, within the top 5% of oncology titles.
“On behalf of ESMO, I extend our profound gratitude to the outgoing Editor-in-Chief, Professor Jean-Charles Soria. Under his focused and truly visionary leadership, Annals of Oncology grew its influence at a time of very exciting developments in oncology. The journal has undoubtedly reached impressive new heights as evidenced by its present impact factor” said Professor Fortunato Ciardiello, ESMO President. “I am pleased to announce that Professor Fabrice André is stepping in as interim Editor-in-Chief with immediate effect. His commitment to the evolution of Annals of Oncology has already been amply proven during his time as its Associate Editor. Professor André is a leading researcher of global reputation and a dedicated member of the ESMO community. I am confident that in his capable hands Annals of Oncology will continue to grow in leaps and bounds”, said Professor Ciardiello.
Fabrice André is currently Professor in the Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.
His research work in the field of biomarkers and personalised therapies focuses on biomarker discovery, development of targeted agents and implementation of personalised medicine. He is also leading phase I-III trials testing targeted agents in the field of breast cancer and large national trials testing implementation of high throughput technologies in the health care system.
Professor André has published more than 200 peer reviewed papers, including papers in the New England Journal of Medicine, Lancet, Nature Medicine, Science, Lancet Oncology and Journal of Clinical Oncology, either as main or co-author. He is chairman of the biomarker group at UNICANCER (French cooperative group).
Professor André has been a member of the ESMO Educational Committee since 2009; a member of the Annals of Oncology Editorial Board (2010-2013) and Associate Editor since 2014.
He is currently chair of the ESMO Translational Research and Personalised Medicine Working Group.
“I am deeply honoured to be chosen by ESMO as interim Editor-in-Chief of Annals of Oncology. The achievements of the journal in recent years make this assignment a unique and very exciting challenge. I am very happy to take it on and I look forward to working with the Editorial Board so that the Annals of Oncology success story has the sequel it deserves” said Professor Fabrice André, MD, PhD.
About the European Society for Medical Oncology (ESMO)
ESMO is the leading professional organisation for medical oncology. With 16,000 members representing oncology professionals from over 130 countries worldwide, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.
About Annals of Oncology
Annals of Oncology, the journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, provides rapid and efficient peer-review publications on innovative cancer treatments or translational work related to oncology and precision medicine.